New Medical Technology Company CareFusion Spins Off From Cardinal Health
San Diego, CA
Cardinal Health announced it has completed the spinoff of CareFusion Corp. through a pro rata distribution of approximately 81 percent of the shares of CareFusion common stock, launching it as an independent, publicly traded company.
“Our experienced management team and more than 15,000 employees begin ready to serve our global customers as a new public company,” said David L. Schlotterbeck, the named Chairman.
CareFusion opens regular-way trading on the New York Stock Exchange and will be included in the S&P 500 index. The new medical technology company is a leading provider of clinically proven products and services that help health care institutions worldwide measurably improve patient care.
Among other items, the CareFusion board of directors acted yesterday to name Schlotterbeck, 62, as chairman in addition to his existing CEO role, and Michael Losh, 63, as presiding director.
Cardinal Health distributed to its shareholders 0.5 shares of CareFusion common stock for each outstanding Cardinal Health common share held as of market close on Aug. 25. In addition, Cardinal Health retained approximately 41 million shares, which pursuant to the IRS private letter ruling for the spinoff, it is required to divest within five years. Including shares held by Cardinal Health, there are approximately 222 million shares of CareFusion common stock outstanding following the spinoff.
See the company press release.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
